@article{TLCR336,
author = {Martin Früh and Miklos Pless},
title = {EGFR IHC score for selection of cetuximab treatment: Ready for clinical practice?},
journal = {Translational Lung Cancer Research},
volume = {1},
number = {2},
year = {2012},
keywords = {},
abstract = {The discovery of activating epidermal growth factor receptor (EGFR) mutations and the anaplastic lymphoma kinase gene rearrangement led to significantly improved outcomes with EGFR-tyrosine kinase inhibitors (TKIs) and crizotinib, respectively. These results have revolutionized treatment algorithms in non-small cell lung cancer (NSCLC), which are now, - at least in part-, biomarker-guided. The advantage of this approach is obvious, allowing active treatments to be offered to a selected group of patients who are more likely to benefit.},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/336}
}